Cell type-specific enhancers regulate IL-22 expression in innate and adaptive type 3 lymphoid cells
IL-22, a signature cytokine for type 3 lymphoid cells, including T helper 17/22 (Th17/22) and type 3 innate lymphoid cells (ILC3), mediates epithelial homeostasis and protective pathogen responses in barrier tissues. Upon dysregulation, IL-22 can drive chronic inflammatory diseases, yet little is known about transcriptional elements modulating its expression. Here, we identify two enhancers, E22-1 and E22-2, with distinct capacities for regulating Il22 expression in type 3 lymphoid cells. Both enhancers are necessary for protection from Citrobacter rodentium infection and for the onset of IL-22-mediated psoriasis. E22-2 is specifically required for IL-22 expression in ILC3s, while E22-1 functions in both Th17/22 and ILC3. The ILC3 specificity of E22-2 is attributed to the presence of multiple Runx3 sites and the lack of a functional RORγt motif. We conclude that Th17/22 and ILC3 cells use distinct cis-elements to differentially regulate IL-22 expression, while orchestrating homeostatic protection and pathogen defense in barrier tissues.
Authors
- Katharina E. Hayer
- Rebecca A. Glynn (ORCID: https://orcid.org/0000-0002-3916-6900)
- Craig H. Bassing (ORCID: https://orcid.org/0000-0003-1703-0786)
- Leone S. Hopkins (ORCID: https://orcid.org/0009-0007-7902-779X)
- Eugene M. Oltz (ORCID: https://orcid.org/0000-0002-2513-7156)
- Nicholas G Selner
- Vanida A. Serna
- Matthew McCullen (ORCID: https://orcid.org/0000-0001-9138-1483)
- Ankita Saini (ORCID: https://orcid.org/0009-0000-3694-495X)
- José Luís Fachi
- Bishan Bhattarai
- Marco Colonna
Institutions
- Children's Hospital of Philadelphia (US)
- Washington University in St. Louis (US)
- The Ohio State University (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-03-14
- DOI
- https://doi.org/10.1038/s41467-026-70636-4
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ohio State University
- Pelotonia
- National Institutes of Health